METASTATIC NON SMALL CELL LUNG CANCER

This phase 2 trial tested whether adding relatlimab to the standard immunotherapy nivolumab plus chemotherapy could shrink tumors better in people with advanced or recurrent non-small cell lung cancer. About 468 participants received either the two-immunotherapy combo with chemo …

This phase 3 trial tested a new immunotherapy combination (pembrolizumab plus vibostolimab) with chemotherapy against the standard pembrolizumab-plus-chemotherapy for people with advanced non-small cell lung cancer. The study enrolled 739 participants who had not received prior t…

This study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visib…

This early-phase study tested the safety of combining two targeted drugs, dacomitinib and osimertinib, in 22 people with a specific type of advanced lung cancer (EGFR mutant). Participants had not received similar targeted therapy before. The goal was to find the safest dose and …

This phase 2 trial tested two drugs, amivantamab and lazertinib, in 43 adults with a specific type of lung cancer (EGFR-mutant) that had spread to the brain and worsened after previous treatments. The goal was to see if the combination could shrink or control brain tumors. Both d…

This study tested a program called LiveWell, which teaches practical skills to help people with metastatic lung cancer manage stress, anxiety, and sadness. One participant completed the 8-session video-based training. The goal was to see if the program is usable and helpful for i…

This study looked at 115 adults with advanced non-small cell lung cancer to see if muscle loss (sarcopenia) and a blood-based score called CTI affect how well immunotherapy works. Researchers reviewed medical records to measure muscle on CT scans and calculate CTI from routine bl…

This study looked at 100 people with advanced non-small cell lung cancer to see if changes in tumor DNA in the blood (ctDNA) can predict how well treatment is working. Researchers took blood samples before treatment, at 3 weeks, and at 9 weeks. The goal was to see if a rise or fa…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…